Stevens J - Search Results

1

Exposure-Response Analysis of the Sodium-Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes.

van der Hoek S, Koomen JV, van Bommel EJM, Mosterd CM, Scholtes RA, Hesp AC, Stevens J, van Raalte DH, Heerspink HJL. van der Hoek S, et al. Among authors: stevens j. J Pers Med. 2023 Apr 27;13(5):747. doi: 10.3390/jpm13050747. J Pers Med. 2023. PMID: 37240917 Free PMC article.

2

Exposure-response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials.

Koomen JV, Stevens J, Heerspink HJL. Koomen JV, et al. Among authors: stevens j. Br J Clin Pharmacol. 2020 Nov;86(11):2192-2203. doi: 10.1111/bcp.14318. Epub 2020 May 10. Br J Clin Pharmacol. 2020. PMID: 32311110 Free PMC article.

3

Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight.

Koomen JV, Stevens J, Mostafa NM, Parving HH, de Zeeuw D, Heerspink HJL. Koomen JV, et al. Among authors: stevens j. Diabetes Obes Metab. 2018 Aug;20(8):2019-2022. doi: 10.1111/dom.13312. Epub 2018 May 1. Diabetes Obes Metab. 2018. PMID: 29603851 Free PMC article. Clinical Trial.

4

Exposure-response relationships for the sodium-glucose co-transporter-2 inhibitor dapagliflozin with regard to renal risk markers.

Kroonen MYAM, Koomen JV, Petrykiv SI, Laverman GD, Heerspink HJL, Stevens J. Kroonen MYAM, et al. Among authors: stevens j. Diabetes Obes Metab. 2020 Jun;22(6):916-921. doi: 10.1111/dom.13976. Epub 2020 Feb 17. Diabetes Obes Metab. 2020. PMID: 31984620 Free PMC article. Clinical Trial.

5

Evaluation of the Pharmacokinetics and Exposure-Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease.

van der Aart-van der Beek AB, Koomen JV, Dekkers CCJ, Barbour SJ, Boulton DW, Gansevoort RT, Greasley PJ, Abdul Gafor AH, Laverman GD, Li Q, Lim SK, Stevens J, Vervloet MG, Singh S, Cattran DC, Reich HN, Cherney DZI, Heerspink HJL. van der Aart-van der Beek AB, et al. Among authors: stevens j. Clin Pharmacokinet. 2021 Apr;60(4):517-525. doi: 10.1007/s40262-020-00956-1. Epub 2021 Feb 15. Clin Pharmacokinet. 2021. PMID: 33587286 Free PMC article. Clinical Trial.

6

GMP Compliant Synthesis of [¹⁸F]Canagliflozin, a Novel PET Tracer for the Sodium-Glucose Cotransporter 2.

van der Hoek S, Antunes IF, Attia KA, Jacquet O, Heeres A, Bulthuis M, Zijlma R, Boersma HH, van Goor H, Visser TJ, Heerspink HJL, Elsinga PH, Stevens J. van der Hoek S, et al. Among authors: stevens j. J Med Chem. 2021 Nov 25;64(22):16641-16649. doi: 10.1021/acs.jmedchem.1c01269. Epub 2021 Nov 8. J Med Chem. 2021. PMID: 34748702 Free PMC article.

7

Current Use and Complementary Value of Combining in Vivo Imaging Modalities to Understand the Renoprotective Effects of Sodium-Glucose Cotransporter-2 Inhibitors at a Tissue Level.

van der Hoek S, Stevens J. van der Hoek S, et al. Among authors: stevens j. Front Pharmacol. 2022 Feb 21;13:837993. doi: 10.3389/fphar.2022.837993. eCollection 2022. Front Pharmacol. 2022. PMID: 35264970 Free PMC article. Review.

8

Studying Telmisartan Plasma Exposure, Kidney Distribution, Receptor Occupancy, and Response in Patients With Type 2 Diabetes Using [¹¹ C]Telmisartan.

van der Hoek S, Mulder DJ, Willemsen ATM, Visser T, Heeres A, Slart RHJA, Elsinga PH, Heerspink HJL, Stevens J. van der Hoek S, et al. Among authors: stevens j. Clin Pharmacol Ther. 2022 Dec;112(6):1264-1270. doi: 10.1002/cpt.2744. Epub 2022 Sep 30. Clin Pharmacol Ther. 2022. PMID: 36070078 Free PMC article.

9

Feasibility Study to Assess Canagliflozin Distribution and Sodium-Glucose Co-Transporter 2 Occupancy Using [¹⁸ F]Canagliflozin in Patients with Type 2 Diabetes.

van der Hoek S, Willemsen ATM, Visser T, Heeres A, Mulder DJ, Bokkers RPH, Slart RHJA, Elsinga PH, Heerspink HJL, Stevens J. van der Hoek S, et al. Among authors: stevens j. Clin Pharmacol Ther. 2023 Jun;113(6):1295-1303. doi: 10.1002/cpt.2886. Epub 2023 Mar 26. Clin Pharmacol Ther. 2023. PMID: 36897753

10

Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin.

Kroonen MYAM, Stevens J, de Zeeuw D, Heerspink HJL. Kroonen MYAM, et al. Among authors: stevens j. Diabetes Obes Metab. 2019 Dec;21(12):2635-2642. doi: 10.1111/dom.13849. Epub 2019 Sep 30. Diabetes Obes Metab. 2019. PMID: 31414562 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,426 results

Search Page